Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Increase in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 497,000 shares, a growth of 228.5% from the November 30th total of 151,300 shares. Based on an average daily trading volume, of 1,660,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 5.6% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $7.00 price target on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

Windtree Therapeutics Stock Performance

Shares of WINT opened at $0.32 on Friday. The firm has a market cap of $2.83 million, a P/E ratio of -0.02 and a beta of 0.54. Windtree Therapeutics has a twelve month low of $0.29 and a twelve month high of $14.75. The firm’s 50 day moving average price is $0.55 and its two-hundred day moving average price is $3.38.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.